GU Cancers 2019 | Enzalutamide in the non-metastatic setting for CRPC
Enzalutamide has shown to improve outcomes in metastatic castration resistant prostate cancer, however how can this therapy benefit patients who do not have metastatic disease? Orazio Caffo, MD, of the Santa Chiara Hospital, Trento, Italy, discusses his views on the use of enzalutamide in the non-metastatic setting, at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.
Transcript (edited for clarity)
I think it’s a great drug, because in non-metastatic disease, it may act to delay the appearance of metastatic disease. This is a great opportunity, in my opinion, but we don’t know what happens when this drug is administered for a very long-term time. This may be a limitation, in this case...
I think it’s a great drug, because in non-metastatic disease, it may act to delay the appearance of metastatic disease. This is a great opportunity, in my opinion, but we don’t know what happens when this drug is administered for a very long-term time. This may be a limitation, in this case.
Read more...
